title: Chronic hepatitis B with type I diabetes mellitus and autoimmune thyroiditis development during interferon alpha therapy.
abstract: Interferon alpha is a molecule frequently used in the treatment of chronic hepatitis B, C, and D, with immunomodulatory and antiviral activity. It is also used in some cancer types. It has been widely claimed that interferon alpha triggers autoimmunity, with its broad adverse effect profile. Here we present the case of a 29-year-old male patient with chronic hepatitis B diagnosis who developed type 1 diabetes mellitus and autoimmune thyroiditis during treatment with interferon alfa-2b. Within four months of initiation of treatment with interferon alfa-2b, the patient presented to our clinic with dry mouth, urinary frequency (8 to 10 times per day), drinking plenty of water, night time urination, and tiredness. He was admitted to the clinic when his fasting blood glucose level was detected to be high. After examinations, the patient was diagnosed with type 1 diabetes and autoimmune thyroiditis and began to receive treatment with insulin and propranolol. Fasting blood glucose levels were controlled and thyroid hormones decreased to normal levels within one month after the treatments began. For patients who will receive treatment with interferon alpha, especially those individuals with chronic hepatitis, pancreatic autoantibodies should be checked and close monitoring should be performed as there may be glucose tolerance impairment in patients with high titers. In addition, follow-up with thyroid function tests should be performed prior to and during the treatment.
authors.affiliation: Tepecik Education and Research Hospital Department of Infectious Diseases and Clinical Microbiology, Izmir, Turkey. sukrankose@yahoo.com
authors.forename: Sukran
authors.initials: S
authors.lastname: Kose
authors.forename: Ayhan
authors.initials: A
authors.lastname: Gozaydin
authors.forename: Gulgun
authors.initials: G
authors.lastname: Akkoclu
authors.forename: Gulfem
authors.initials: G
authors.lastname: Ece
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage; D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects*; D003922:Diabetes Mellitus, Type 1 / Q000150:complications*; D019694:Hepatitis B, Chronic / Q000150:complications*; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage; D007155:Immunologic Factors / Q000008:administration & dosage / Q000009:adverse effects*; D007328:Insulin / Q000008:administration & dosage; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D011433:Propranolol / Q000008:administration & dosage; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects; D013967:Thyroiditis, Autoimmune / Q000139:chemically induced*
chemical_list: D000319:Adrenergic beta-Antagonists; D000998:Antiviral Agents; D007004:Hypoglycemic Agents; D007155:Immunologic Factors; D007328:Insulin; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011433:Propranolol